Förderung der Impfstoffentwicklung und -produktion in Südafrika Support of development and production of vaccines in South Africa Das Modulziel ist es, die Impfstoffwertschöpfungskette in Südafrika zu stärken und dadurch die lokale Entwicklung von APIs für die Impfstoffproduktion (auch jenseits von Covid-19 Impfstoffen) zu ermöglichen. Dies erfolgt durch die Beschaffung von Equipment für den Betrieb von Pilotanlagen für die Produktion von Impfstoffen für klinische Studien, die Modernisierung der Labor- und Forschungseinrichtungen zur Impfstoffentwicklung und durch die Stärkung der nationalen Regulierungsbehörde, inkl. deren Referenzlabor für die Zertifizierung von neuen Medizinprodukten. Der Zugang zu lokal hergestellten API und deren Produktion für klinische Studien wird somit ermöglicht. Dies senkt die Importabhängigkeit Südafrikas, die wie im gesamten Afrika sehr hoch ist. Durch die Stärkung der nationalen Regulierungsbehörde können Impfstoffe WHO-konform zertifiziert werden, was wiederum den Export der vor Ort hergestellten Produkte und deren Abnahme durch GAVI ermöglicht. Somit kann das Vorhaben indirekt dazu beitragen, die Krankheitslast der Bevölkerung auf dem afrikanischen Kontinent und den Entwicklungsländern zu senken. Begünstigter des Zuschusses ist die Republik Südafrika, vertreten durch das Department of Science and Innovation (DSI). Projektträger der FZ-Maßnahme ist das South African Medical Research Council (MRC). The module objective is to strengthen the vaccine value chain in South Africa, thereby enabling the local development of APIs for vaccine production (also beyond Covid-19 vaccines). This is done by procuring equipment to operate pilot plants for the production of vaccines for clinical trials, upgrading laboratory and research facilities for vaccine development, and strengthening the national regulatory authority, including its reference laboratory for the certification of new medical devices. Access to locally produced APIs and their production for clinical trials is thus made possible. This reduces South Africa's dependence on imports, which is very high, as it is in Africa as a whole. By strengthening the national regulatory authority, vaccines can be certified WHO-compliant, which in turn enables the export of locally manufactured products and their acceptance by GAVI. Thus, the project can indirectly contribute to reducing the disease burden of the population on the African continent and in developing countries. The beneficiary of the grant is the Republic of South Africa, represented by the Department of Science and Innovation (DSI). The project executing agency of the FC measure is the South African Medical Research Council (MRC). Verbesserung der Impfstoffversorgung in Südafrika The module objective is to strengthen the vaccine value chain in South Africa, thereby enabling the local development of APIs for vaccine production (also beyond Covid-19 vaccines). This is done by procuring equipment to operate pilot plants for the production of vaccines for clinical trials, upgrading laboratory and research facilities for vaccine development, and strengthening the national regulatory authority, including its reference laboratory for the certification of new medical devices. Access to locally produced APIs and their production for clinical trials is thus made possible. This reduces South Africa's dependence on imports, which is very high, as it is in Africa as a whole. By strengthening the national regulatory authority, vaccines can be certified WHO-compliant, which in turn enables the export of locally manufactured products and their acceptance by GAVI. Thus, the project can indirectly contribute to reducing the disease burden of the population on the African continent and in developing countries. The beneficiary of the grant is the Republic of South Africa, represented by the Department of Science and Innovation (DSI). The project executing agency of the FC measure is the South African Medical Research Council (MRC).